Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: Results from the Norfolk Arthritis Register

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1139-1144

  Humphreys, Jennifer H ^a   Verheul, Marije K ^b   Barton, Anne ^c,d   MacGregor, Alexander J ^a   Lunt, Mark ^a   Toes, Rene E M ^b   Symmons, Deborah P M ^a,d   Trouw, Leendert A ^b   Verstappen, Suzanne M M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CARBAMYLATED PROTEIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARBAMIC ACID DERIVATIVE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYARTHRITIS; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; SWELLING; AGED; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; REGISTER; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; CARBAMATES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; REGISTRIES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 84971350689     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207326     Document Type: Article

References (29)

1. van der Helm-van Mil AH, Breedveld FC, Huizinga TW. Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 2006;8:216.
2. Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2014;66:1296-301.
3. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006;45:478-80.
4. De RL, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
5. Shidara K, Inoue E, Hoshi D, et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int 2012;32:361-6.
6. Humphreys JH, van Nies J, Chipping J, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014;16:483.
7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
8. Humphreys JH, Symmons DP. Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: where do we stand? Curr Opin Rheumatol 2013;25:157-63.
9. Jung SJ, Lee SW, Ha YJ, et al. Patients with early arthritis who fulfil the 1987 ACR classification criteria for rheumatoid arthritis but not the 2010 ACR/EULAR criteria. Ann Rheum Dis 2012;71:1097-8.
10. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011;108:17372-7.
11. Burska AN, Hunt L, Boissinot M, et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm 2014;2014:492873.
12. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014;73:780-3.
13. Gan RW, Trouw LA, Shi J, et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol 2015;42:572-9.
14. Brink M, Verheul MK, Ronnelid J, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015;17:536.
15. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013;65:911-15.
16. Symmons DP, Silman AJ. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Res Ther 2006;8:214.
17. Department of Rheumatology UMCNN. DAS28. 2004. http://www.das-score.nl/
18. Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480-8.
19. van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011;63:37-42.
20. Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012;8:573-86.
21. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7:e35296.
22. Nielen MM, Van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
23. Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 2015;74:2151-6.
24. Yee A, Webb T, Seaman A, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 2015;61:24-30.
25. Montes A, Perez-Pamoin E, Boveda MD, et al. Antibodies against carbamylated proteins (anti-CarP), a new type of autoantibody, in Spanish patients with rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl 2):129.
26. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
27. Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 2009;36:254-9.
28. Wiles N, Symmons DP, Harrison B, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999;42:1339-46.
29. Burgers LE, van Nies JA, Ho LY, et al. Long-term outcome of rheumatoid arthritis defined according to the 2010-classification criteria. Ann Rheum Dis 2014;73:428-32.